ABPRO HLDGS INC（以下简称Abpro）近日宣布，通过与韩国生物制药企业Celltrion的全球战略合作，其创新药物临床试验计划预计将于2026年上半年正式启动。此次合作将整合Abpro在抗体疗法领域的技术优势与Celltrion的规模化生产实力，共同推进肿瘤治疗领域的研发进程。
根据双方协议，Abpro将负责前期研发及临床方案设计，Celltrion则承担临床阶段的生产供应与全球商业化支持。该合作模式有望加速药物上市周期，为患者提供更前沿的治疗选择。目前双方已就具体试验方案展开深度对接，相关监管审批准备工作同步推进中。
行业分析指出，此次跨国合作凸显了生物技术企业与传统药企资源互补的趋势。Abpro凭借其专有的抗体发现平台，近年来在双特异性抗体领域取得突破性进展，而Celltrion在全球生物类似药市场的渠道优势将为合作产品提供更广阔的商业化空间。此次临床试验的推进，或将成为评估创新疗法有效性的重要里程碑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.